Drugs / Mavoglurant
Trials 26
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05203965 | May 2022 → May 2026 | — | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT03341715 | Jun 2018 → Nov 2019 | — | Yale University | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT06136195 | Jul 2024 → May 2027 expected | alcohol-related disorders | Yale University | Recruiting | No outcome recorded |
| Phase 1 | NCT06273540 | Apr → Oct 2024 | substance-related disorder | Stalicla SA | Completed | No outcome recorded |
| Phase 1 | NCT04771143 | Jul 2021 → Jan 2022 | substance-related disorder | Novartis Pharmaceuticals | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03327792 | Feb 2018 → Jul 2023 | alcohol-related disorders | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT01482143 | Mar 2012 → Oct 2013 | fragile X syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01456663 | May 2011 → Jul 2012 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01442259 | Jan → Aug 2011 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00414856 | Aug 2006 → ? | gastroesophageal reflux disease | Novartis | Completed | No outcome recorded |
| Phase 215 trials · 2 met primary · 7 missed | ||||||
| Phase 2 | NCT03242928 | Dec 2017 → Dec 2019 | cocaine dependence | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT02920892 | Aug 2017 → May 2022 | fragile X syndrome | Elizabeth Berry-Kravis | Completed | Missed primary |
| Phase 2 | NCT01813019 | Nov 2013 → Nov 2014 | — | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 2 | NCT01491529 | Apr 2012 → Apr 2013 | Parkinson disease, drug-induced dyskinesia, movement disorder | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01491932 | Mar 2012 → Oct 2013 | Parkinson disease, drug-induced dyskinesia, movement disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01385592 | Nov 2011 → Sep 2012 | Parkinson disease, movement disorder | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01348087 | Aug 2011 → Sep 2014 | fragile X syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01357239 | May 2011 → Jan 2014 | fragile X syndrome | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01253629 | Nov 2010 → Aug 2013 | fragile X syndrome | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01173731 | Oct 2010 → Oct 2013 | Parkinson disease, autosomal dominant dopa-responsive dystonia, drug-induced dyskinesia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01092065 | Mar 2010 → Jul 2011 | Parkinson disease | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT01019473 | Nov 2009 → Aug 2011 | Huntington disease, choreatic disease | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 2 | NCT00986414 | Sep 2009 → Dec 2010 | Parkinson disease, drug-induced dyskinesia | Novartis | Completed | Met primary |
| Phase 2 | NCT00888004 | Mar → Aug 2009 | Parkinson disease, drug-induced dyskinesia | Novartis | Completed | Mixed |
| Phase 2 | NCT00582673 | Oct 2007 → May 2008 | Parkinson disease | Novartis | Completed | Mixed |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01433354 | Nov 2011 → Sep 2014 | fragile X syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00718341 Comparator | Jun 2008 → Feb 2009 | fragile X syndrome | Novartis | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-05-02 | Stalicla SA | STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) stalicla.com ↗ |
| 2023-03-08 | Stalicla SA | STALICLA signs with National Institute on Drug Abuse (NIDA) for Phase 3 development of mavoglurant in cocaine use disorder stalicla.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mavoglurant | “A phase II randomized, placebo-controlled, double-blind study and subsequent open-label extension study evaluated the efficacy, safety, and tolerability of mavoglurant...” PMID 26855682 ↗ Dec 20158“evaluated the efficacy, safety, and tolerability of mavoglurant (AFQ056), a selective metabotropic glutamate receptor subtype-5 antagonist, in treating behavioral symptoms in...” PMID 26855682 ↗ Dec 2015 “This study investigated the hypothesis that AFQ056 (mavoglurant), a selective metabotropic glutamate receptor 5 antagonist, reduces chorea in Huntington's disease (HD).” PMID 25689146 ↗ Feb 2015 “Patients were randomized to mavoglurant 100-mg or placebo (4:3) groups (study 1) and mavoglurant 200-mg, mavoglurant 150-mg, or placebo (2:1:1) groups (study 2).” PMID 27214258 ↗ May 2016 |
| Known as | AFQ056 | “We examined whether a receptor subtype-selective inhibitor of mGluR5, AFQ056, improves the behavioral symptoms of FXS in a randomized, double-blind, two-treatment, two-period,...” PMID 21209411 ↗ Jan 201122“evaluated the efficacy, safety, and tolerability of mavoglurant (AFQ056), a selective metabotropic glutamate receptor subtype-5 antagonist, in treating behavioral symptoms in...” PMID 26855682 ↗ Dec 2015 “Mavoglurant (AFQ056)” NCT05203965 ↗ |
| Known as | STP7 | “STP7 (mavoglurant) twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID” NCT06273540 ↗ |
| Action | Inhibit | “a receptor subtype-selective inhibitor of mGluR5, AFQ056” PMID 21209411 ↗ Jan 20111“Metabotropic glutamate receptor 5 antagonist” CHEMBL3087515 ↗ |
| Modality | Small molecule | — CHEMBL3087515 ↗ |
| Route | Oral | “oral single dose applications” NCT00414856 ↗ |
| Target | GRM5 | “Metabotropic glutamate receptor 5 antagonist” CHEMBL3087515 ↗ |